- Home
- AKRO vs OMCL Comparison
AKRO vs OMCL Comparison
Compare AKRO & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- OMCL
- Stock Information
- Founded
- AKRO 2017
- OMCL 1992
- Country
- AKRO United States
- OMCL United States
- Employees
- AKRO N/A
- OMCL N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- AKRO Health Care
- OMCL Technology
- Exchange
- AKRO Nasdaq
- OMCL Nasdaq
- Market Cap
- AKRO 3.9B
- OMCL 1.3B
- IPO Year
- AKRO 2019
- OMCL 2001
- Fundamental
- Price
- AKRO $51.69
- OMCL $28.69
- Analyst Decision
- AKRO Strong Buy
- OMCL Buy
- Analyst Count
- AKRO 6
- OMCL 6
- Target Price
- AKRO $82.50
- OMCL $44.83
- AVG Volume (30 Days)
- AKRO 1.6M
- OMCL 427.8K
- Earning Date
- AKRO 08-08-2025
- OMCL 07-31-2025
- Dividend Yield
- AKRO N/A
- OMCL N/A
- EPS Growth
- AKRO N/A
- OMCL N/A
- EPS
- AKRO N/A
- OMCL 0.45
- Revenue
- AKRO N/A
- OMCL $1,135,755,000.00
- Revenue This Year
- AKRO N/A
- OMCL $3.84
- Revenue Next Year
- AKRO N/A
- OMCL $3.98
- P/E Ratio
- AKRO N/A
- OMCL $63.34
- Revenue Growth
- AKRO N/A
- OMCL 3.00
- 52 Week Low
- AKRO $21.34
- OMCL $22.66
- 52 Week High
- AKRO $58.40
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- AKRO 45.35
- OMCL 43.98
- Support Level
- AKRO $50.13
- OMCL $28.81
- Resistance Level
- AKRO $53.60
- OMCL $30.19
- Average True Range (ATR)
- AKRO 2.03
- OMCL 0.88
- MACD
- AKRO -0.83
- OMCL 0.02
- Stochastic Oscillator
- AKRO 6.37
- OMCL 34.49
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.